Blockchain Registration Transaction Record

GLP-1 Meds Slash Amputations and Deaths in Diabetes Patients with PAD

GLP-1 medications reduce amputations, deaths, and hospitalizations in Type 2 diabetes patients with peripheral artery disease (PAD), according to new research in the Journal of the American Heart Association.

This news matters because it offers a new, powerful tool for millions of patients with Type 2 diabetes and peripheral artery disease, a condition with limited treatment options. GLP-1 RAs could dramatically reduce amputations and prolong life, especially for those with severe PAD or obesity, potentially transforming standard care and improving quality of life for a high-risk population.